IL161543A0 - NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE - Google Patents

NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE

Info

Publication number
IL161543A0
IL161543A0 IL16154302A IL16154302A IL161543A0 IL 161543 A0 IL161543 A0 IL 161543A0 IL 16154302 A IL16154302 A IL 16154302A IL 16154302 A IL16154302 A IL 16154302A IL 161543 A0 IL161543 A0 IL 161543A0
Authority
IL
Israel
Prior art keywords
receptors
methods
human primate
primate
human
Prior art date
Application number
IL16154302A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL161543A0 publication Critical patent/IL161543A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL16154302A 2001-12-19 2002-12-03 NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE IL161543A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/027,736 US6911321B2 (en) 2001-12-19 2001-12-19 Non-human primate Fc receptors and methods of use
PCT/US2002/038805 WO2003054213A2 (fr) 2001-12-19 2002-12-03 Recepteurs de primates non humains et leur procede d'utilisation

Publications (1)

Publication Number Publication Date
IL161543A0 true IL161543A0 (en) 2004-09-27

Family

ID=21839483

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16154302A IL161543A0 (en) 2001-12-19 2002-12-03 NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE

Country Status (7)

Country Link
US (3) US6911321B2 (fr)
EP (1) EP1456222A4 (fr)
JP (1) JP2005512574A (fr)
AU (1) AU2002357071A1 (fr)
CA (1) CA2466885A1 (fr)
IL (1) IL161543A0 (fr)
WO (1) WO2003054213A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP3993783B2 (ja) * 2002-04-04 2007-10-17 株式会社小糸製作所 車両用灯具の設計方法、設計システム、プログラム、及び記録媒体
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
CA2512974A1 (fr) * 2003-01-13 2004-07-29 Macrogenics, Inc. Proteines de fusion fc.gamma.r solubles et leurs procedes d'utilisation
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
CA2545603A1 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
AU2004293184B2 (en) * 2003-11-26 2010-12-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Substance binding human IgG Fc receptor IIb
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
EP1737890A2 (fr) * 2004-03-24 2007-01-03 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
WO2006031994A2 (fr) * 2004-09-14 2006-03-23 Xencor, Inc. Domaines fc monomeres des immunoglobulines
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP2845865A1 (fr) 2004-11-12 2015-03-11 Xencor Inc. Variantes Fc avec liaison altérée en FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2595169A1 (fr) * 2005-01-12 2006-07-20 Xencor, Inc. Anticorps et proteines de fusion fc a immunogenicite modifiee
CA2624189A1 (fr) * 2005-10-03 2007-04-12 Xencor, Inc. Variants de fc dotes de proprietes de liaison aux recepteurs fc optimisees
EP1951757B1 (fr) 2005-10-06 2014-05-14 Xencor, Inc. Anticorps anti-cd30 optimises
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
WO2008028068A2 (fr) * 2006-08-30 2008-03-06 Genentech, Inc. POLYPEPTIDES FCεR1α DE PRIMATES NON HUMAINS
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
EP1997830A1 (fr) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
EP3825329A1 (fr) 2007-12-26 2021-05-26 Xencor, Inc. Variants fc avec liaison altérée à fcrn
WO2010068722A1 (fr) 2008-12-12 2010-06-17 Medimmune, Llc Cristaux et structure d'un variant de fc d'igg humain avec liaison augmentée à fcrn
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
JP5812627B2 (ja) * 2010-03-10 2015-11-17 公益財団法人相模中央化学研究所 改良Ｆｃ受容体およびその製造方法
CN105555801B (zh) * 2013-09-18 2020-05-05 东曹株式会社 Fc结合性蛋白质、该蛋白质的制造方法和使用了该蛋白质的抗体吸附剂、以及使用了该吸附剂的抗体的纯化方法及识别方法
ES2794942T3 (es) * 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
EP3702462B1 (fr) 2017-10-27 2024-10-09 Tosoh Corporation Protéine de liaison à fc présentant une résistance alcaline améliorée, procédé de production de ladite protéine, anticorps adsorbant utilisant ladite protéine, et procédés de séparation d'anticorps au moyen dudit adsorbant
CN116769014A (zh) * 2023-06-07 2023-09-19 河南省农业科学院动物免疫学重点实验室 一种牛IgG Fc受体boFcγRI的线性配体结合表位

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
AU6668094A (en) * 1993-04-23 1994-11-21 Sloan-Kettering Institute For Cancer Research Method for screening for targets for anti-inflammatory or anti-allergic agents
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies

Also Published As

Publication number Publication date
EP1456222A2 (fr) 2004-09-15
US6911321B2 (en) 2005-06-28
US20050054046A1 (en) 2005-03-10
JP2005512574A (ja) 2005-05-12
EP1456222A4 (fr) 2006-12-06
WO2003054213A2 (fr) 2003-07-03
AU2002357071A1 (en) 2003-07-09
US20070106069A1 (en) 2007-05-10
WO2003054213A3 (fr) 2004-01-22
US20030190614A1 (en) 2003-10-09
CA2466885A1 (fr) 2003-07-03

Similar Documents

Publication Publication Date Title
IL161543A0 (en) NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE
IL265538B (en) Optimal variants of fc and their uses
HK1060727A1 (en) Antagonists of mcp-1 function and methods of use thereof
HK1079789A1 (zh) 血管靜態毒性試劑及其使用方法
EP1461430A4 (fr) Promoteur de l'ovomucoide et procedes d'utilisation
HK1060728A1 (en) Antagonists of mcp-1 function and methods of use thereof
IL157142A0 (en) Modified antibodies and methods of use
AU2002324775A8 (en) Architecture tool and methods of use
IL213648A0 (en) OPTIMIZED Fc VARIANTS AND USES THEREOF
EP1420825A4 (fr) Composes immunomodulants et methodes d'utilisation
EP1416995A4 (fr) Dispositif de sterilisation de fluide par filtration et mode d'utilisation
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
HK1167690A1 (en) Chimeric immunomodulatory compounds and methods of using the same
AU2003288902A8 (en) Microcapsules and methods of use
HK1068874A1 (en) Heterocyclic compounds and methods of use
PT1379504E (pt) Derivados bipiperidinilo e sua utilização como inibidores de receptores de quimioquinas
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2002359512A8 (en) Belts and methods of use thereof
GB2374501B (en) Facilitation of clear presenentation in audio user interface
EP1438387A4 (fr) Procedes de fabrication de glycomolecules a activite amelioree, et utilisations de ces dernieres
PL377617A1 (pl) Retraktor prowadzony i sposoby stosowania
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
IL163926A0 (en) Crystal structure of phosphodiesterase 5 and use thereof
EP1414427A4 (fr) Compositions a base de kavalactone et leurs procedes d'utilisation
EP1412754A4 (fr) Procede et agents diagnostiques